EGFR and breast cancer: Although 50–70% of tumors of the TNBC subtype of breast cancer express EGFR, the therapeutic efficacy of EGFR-targeting agents has been disappointing and despite cytotoxic chemotherapy, the outcome remains poor [9,10,24,25].